Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Benzoyl Peroxide/Tretinoin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Benzoyl Peroxide/Tretinoin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Penpulimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Penpulimab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Atorvastatin/Fimasartan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Atorvastatin/Fimasartan: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Fexuprazan hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Fexuprazan hydrochloride: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Zimberelimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Zimberelimab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Envafolimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Envafolimab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Sirolimus Albumin-Bound Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Sirolimus Albumin-Bound: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Nivolumab/Relatlimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Nivolumab/Relatlimab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Macular telangiectasia type 2 Indication Strategy Report 2026: PHGDH, Trials and Deals
23 July 2026
2026 Macular telangiectasia type 2 strategy: epidemiology, PHGDH biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Proliferative diabetic retinopathy Indication Strategy Report 2026: VEGF-A, Trials and Deals
23 July 2026
2026 Proliferative diabetic retinopathy strategy: epidemiology, VEGF-A biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Neurotrophic keratitis Indication Strategy Report 2026: NGF, Trials and Deals
23 July 2026
2026 Neurotrophic keratitis strategy: epidemiology, NGF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Limbal stem cell deficiency Indication Strategy Report 2026: ABCB5, Trials and Deals
23 July 2026
2026 Limbal stem cell deficiency strategy: epidemiology, ABCB5 biology, clinical competition, recent deals, unmet need and market attractiveness.